Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1) Journal Article


Authors: Janssen, B. V.; van Roessel, S.; van Dieren, S.; de Boer, O.; Adsay, V.; Basturk, O.; Brosens, L.; Campbell, F.; Chatterjee, D.; Chou, A.; Doglioni, C.; Esposito, I.; Feakins, R.; Fuchs, T. L.; Fukushima, N.; Gill, A. J.; Hong, S. M.; Hruban, R. H.; Kaplan, J.; Krasinkas, A.; Luchini, C.; Shi, C.; Singhi, A.; Thompson, E.; Velthuysen, M. L. F.; Besselink, M. G.; Verheij, J.; Wang, H.; Verbeke, C.; Fariña, A.; for the International Study Group of Pancreatic Pathologists (ISGPP)
Article Title: Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1)
Abstract: BACKGROUND: Most tumour response scoring systems for resected pancreatic cancer after neoadjuvant therapy score tumour regression. However, whether treatment-induced changes, including tumour regression, can be identified reliably on haematoxylin and eosin-stained slides remains unclear. Moreover, no large study of the interobserver agreement of current tumour response scoring systems for pancreatic cancer exists. This study aimed to investigate whether gastrointestinal/pancreatic pathologists can reliably identify treatment effect on tumour by histology, and to determine the interobserver agreement for current tumour response scoring systems. METHODS: Overall, 23 gastrointestinal/pancreatic pathologists reviewed digital haematoxylin and eosin-stained slides of pancreatic cancer or treated tumour bed. The accuracy in identifying the treatment effect was investigated in 60 patients (30 treatment-naive, 30 after neoadjuvant therapy (NAT)). The interobserver agreement for the College of American Pathologists (CAP) and MD Anderson Cancer Center (MDACC) tumour response scoring systems was assessed in 50 patients using intraclass correlation coefficients (ICCs). An ICC value below 0.50 indicated poor reliability, 0.50 or more and less than 0.75 indicated moderate reliability, 0.75 or more and below 0.90 indicated good reliability, and above 0.90 indicated excellent reliability. RESULTS: The sensitivity and specificity for identifying NAT effect were 76.2 and 49.0 per cent respectively. After NAT in 50 patients, ICC values for both tumour response scoring systems were moderate: 0.66 for CAP and 0.71 for MDACC. CONCLUSION: Identification of the effect of NAT in resected pancreatic cancer proved unreliable, and interobserver agreement for the current tumour response scoring systems was suboptimal. These findings support the recently published International Study Group of Pancreatic Pathologists recommendations to score residual tumour burden rather than tumour regression after NAT. © The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.
Keywords: neoadjuvant therapy; pancreatic neoplasms; reproducibility; reproducibility of results; observer variation; pathology; pancreas tumor; eosin; eosine yellowish-(ys); humans; human
Journal Title: British Journal of Surgery
Volume: 110
Issue: 1
ISSN: 0007-1323
Publisher: Oxford University Press  
Date Published: 2023-01-01
Start Page: 67
End Page: 75
Language: English
DOI: 10.1093/bjs/znac350
PUBMED: 36331867
PROVIDER: scopus
PMCID: PMC10364538
DOI/URL:
Notes: Article -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Olca Basturk
    352 Basturk